Apellis Pharmaceuticals, Inc. Annual Report - How They Did This Year (Fiscal Year Ended December 31, 2025)

Considering an investment in Apellis Pharmaceuticals? This summary provides a clear, jargon-free overview of their performance for the fiscal year ended December 31, 2025. We'll break down key financial and operational highlights to help you understand the company's position.

1. Business Overview: What does this company do?

Apellis is a biopharmaceutical company that develops and sells innovative treatments for serious diseases. For the fiscal year ending December 31, 2025, their main products and revenue sources were:

• Syfovre (pegcetacoplan injection): This drug treats Geographic Atrophy (GA), a leading cause of blindness linked to age-related macular degeneration (AMD). Syfovre quickly gained market acceptance and significantly boosted revenue.
• Empaveli (pegcetacoplan): Approved for Paroxysmal Nocturnal Hemoglobinuria (PNH), a rare blood disorder. Empaveli continued to serve its patient population, providing a steady revenue stream.
• Aspaveli (pegcetacoplan): Apellis markets this drug outside the U.S. for PNH, primarily through a partnership with Sobi.

This past year, Apellis expanded the market reach of Syfovre and Empaveli, driving overall product sales growth. The company also maintained important research collaborations with Beam Therapeutics Incorporation and the University of Pennsylvania to advance its future drug candidates. Its collaboration and license agreement with Swedish Orphan Biovitrum AB (Sobi) for Aspaveli helped broaden its international presence.

2. Financial Performance: Revenue, Profit, Year-over-Year Changes

Let's examine the numbers for the fiscal year ended December 31, 2025.

Apellis reported total revenue of approximately $650 million, a substantial 35% increase from the previous year. This growth primarily came from:

• Product revenue: Approximately $600 million, largely due to Syfovre's strong market performance and continued Empaveli sales.
• Licensing and other revenue: Roughly $50 million, mainly from their partnership with Sobi.

Despite robust revenue growth, Apellis reported a net loss of approximately $320 million for the year. This is common for biopharmaceutical companies that invest heavily in future growth. Key expenses included:

• Research and Development (R&D): Approximately $400 million, representing about 62% of total revenue. This reflects their commitment to advancing their drug development pipeline.
• Selling, General, and Administrative (SGA): Approximately $450 million, or 69% of total revenue. These costs covered Syfovre's market launch and general operations.

While the company achieved a healthy gross margin on product sales, significant R&D and SGA investments led to the reported net loss. Investors should monitor these expenses relative to revenue growth to gauge the company's path to profitability.

3. Management Discussion and Analysis (MD&A) Highlights: Major Wins and Challenges This Year

Apellis experienced both successes and hurdles this past year.

Major Wins:

• Strong Syfovre Launch & Growth: Syfovre surpassed market expectations, quickly capturing market share in the geographic atrophy treatment space. This successful launch was a significant financial and operational achievement, directly contributing to the substantial revenue growth.
• Strategic Financing: In May 2024, Apellis secured a Senior Secured Credit Facility of up to $300 million through a Sixth Street Financing Agreement. This provided crucial capital to support ongoing operations and future drug development. The company also completed a follow-on public offering in February 2023, raising additional funds to strengthen its financial position.
• Pipeline Advancement: Apellis progressed several early-stage clinical programs, with one drug candidate advancing into Phase 2 trials. This signals future growth potential and justifies R&D investments.

Significant Challenges:

• Syfovre Safety Monitoring: After the drug's release, Apellis received initial reports of rare side effects (such as retinal vasculitis) associated with Syfovre. The company actively engaged with regulators and the medical community to monitor and address these concerns. While the incidence rate remained low, managing public and physician perception required significant management attention and resources.
• Intense Competition: The PNH and GA markets remain highly competitive. This requires continuous innovation and effective commercial strategies to maintain market share against established players and emerging treatments, necessitating ongoing SGA investments.
• High Operating Expenses: Despite revenue growth, substantial R&D and SGA investments resulted in a net loss. This highlights the capital-intensive nature of drug development and sales, and the ongoing need for careful financial management.

4. Financial Health: Cash, Debt, Liquidity

How strong is Apellis financially? As of December 31, 2025, Apellis reported cash and cash equivalents of approximately $480 million. The company holds a significant portion of these funds in secure money market funds.

However, Apellis carries substantial debt:

• Convertible Senior Notes: Approximately $550 million in convertible senior notes are outstanding, maturing in 2026. These notes can convert into company stock under certain conditions, potentially diluting existing shareholders. To manage this, Apellis entered into capped call transactions, financial instruments designed to reduce potential stock dilution if the notes convert.
• Senior Secured Credit Facility: The company drew approximately $150 million from the new Sixth Street facility, adding to its long-term debt.

Overall, Apellis has a total debt burden of approximately $700 million. While its current cash position offers some cushion, managing this debt, especially the 2026 maturities, will be a key focus. The company's current ratio (current assets divided by current liabilities) indicates sufficient liquidity to cover short-term obligations. However, sustained profitability or additional financing will be crucial for long-term financial stability.

5. Risk Factors

Investors should be aware of several significant risks:

• Product Safety and Regulatory Scrutiny: Post-market safety events, like those seen with Syfovre, can lead to increased regulatory oversight, changes to product labeling, or impact how doctors prescribe the drug, potentially hurting sales. Future products also risk failing clinical trials or not receiving regulatory approval.
• Customer Concentration Risk: A substantial portion of Apellis's revenue and money owed to them comes from a few large customers, primarily specialty pharmacies and distributors. For example, "Customer C" and "Customer D" together accounted for over 40% of gross product revenue. If one of these major customers reduces orders, faces financial difficulties, or switches to a competitor, it could severely impact Apellis's revenue and cash flow.
• Intense Competition: The markets for PNH and GA are highly competitive. Established pharmaceutical companies and other biotechs are developing competing treatments. Apellis's products could lose market share if competitors introduce more effective, safer, or cheaper alternatives.
• Financial Obligations and Future Funding: The $550 million convertible senior notes maturing in 2026 represent a significant financial obligation. Apellis will need to either refinance this debt, use existing cash, or issue new equity. Any of these options could impact the company's financial flexibility or shareholder value. Continued operations and drug development will also require substantial future funding.
• Intellectual Property (IP) Protection: Apellis relies heavily on patents and other intellectual property to protect its products. Challenges to their patents or the inability to obtain new ones could allow competitors to enter the market, eroding their competitive advantage.

6. Competitive Position

Apellis operates in highly specialized and competitive therapeutic areas:

• Geographic Atrophy (GA): Syfovre is the first approved treatment for GA, giving Apellis a significant advantage. However, other companies are actively developing treatments, including gene therapies and other complement inhibitors, which could challenge Syfovre's market leadership in the future. Key competitors include large ophthalmology companies.
• Paroxysmal Nocturnal Hemoglobinuria (PNH): Empaveli/Aspaveli competes with established C5 inhibitors. Apellis differentiates itself by targeting C3, offering a different mechanism of action that can help patients who do not respond well to C5 inhibitors. However, the market is mature, and maintaining share requires strong clinical data and patient access.

Apellis's strength lies in its innovative complement inhibition platform, which has produced two approved products. Its challenge is to continue demonstrating superior effectiveness and safety profiles while expanding market access and fending off new competitors.

7. Leadership and Strategy Changes

Apellis saw no major changes in its executive leadership team during the fiscal year. The company's core strategy remains focused on:

• Maximizing Commercial Potential: Driving global adoption and market penetration of Syfovre and Empaveli/Aspaveli.
• Advancing the Pipeline: Investing heavily in R&D to develop new uses for pegcetacoplan and bring novel therapies from their complement inhibition platform into clinical trials.
• Strategic Partnerships: Leveraging collaborations like Sobi to expand international reach and Beam Therapeutics for next-generation therapies.
• Talent Retention: Apellis continues to use various incentive plans, including employee stock options, restricted stock units (RSUs), performance shares, and an employee stock purchase plan, to attract, motivate, and retain top talent essential for their scientific and commercial success.

8. Future Outlook

Looking ahead, Apellis focuses on several key areas:

• Syfovre Expansion: Expect continued efforts to expand Syfovre's market penetration globally, potentially seeking approvals in new regions. The company will also continue to monitor real-world safety data and communicate transparently with the medical community.
• Pipeline Progression: Anticipate updates on their clinical pipeline, with potential for new clinical trial initiations or data releases for earlier-stage drug candidates. They aim to leverage their complement platform for additional indications beyond GA and PNH.
• Financial Management: A critical focus will be on managing the upcoming 2026 convertible note maturities. The company will likely explore refinancing options or strategic use of cash to address this obligation. They also aim to achieve positive cash flow and, eventually, profitability through continued revenue growth and disciplined expense management.
• Partnership Milestones: Future royalty payments from the Sobi collaboration are expected to contribute to revenue, and ongoing research with partners like Beam Therapeutics could yield future product candidates.

9. Market Trends or Regulatory Changes Affecting Them

Apellis operates in a dynamic global healthcare environment, subject to several key trends and potential regulatory shifts:

• Evolving Reimbursement Landscape: Healthcare systems worldwide increasingly focus on value-based care and cost control. Changes in drug pricing policies, reimbursement rates, or coverage criteria, particularly for high-cost specialty drugs like Syfovre and Empaveli, could significantly impact their profitability.
• Increased Regulatory Scrutiny: The pharmaceutical industry faces heightened scrutiny regarding drug safety, manufacturing quality, and promotional practices. Any new regulations from the FDA, EMA, or other international bodies could impact drug development timelines, approval processes, or post-market requirements.
• Global Expansion Challenges: Operating in diverse international markets (including Australia, Switzerland, Bermuda, the UK, Germany, and Italy) means navigating a complex web of different tax laws, healthcare policies, and regulatory pathways. Geopolitical shifts or changes in international trade agreements could also pose challenges.
• Focus on Rare Diseases and Personalized Medicine: A growing trend favors developing therapies for rare diseases and using personalized medicine approaches. Apellis, with its focus on conditions like PNH and GA, is well-positioned within this trend, but competition in these niche areas is also intensifying.